Last reviewed · How we verify
Flu/Cy/ATG or Cy/ATG
A conditioning regimen combining fludarabine, cyclophosphamide, and anti-thymocyte globulin (ATG) to suppress the immune system and prepare patients for hematopoietic stem cell transplantation.
A conditioning regimen combining fludarabine, cyclophosphamide, and anti-thymocyte globulin (ATG) to suppress the immune system and prepare patients for hematopoietic stem cell transplantation. Used for Conditioning prior to allogeneic hematopoietic stem cell transplantation for hematologic malignancies and severe aplastic anemia.
At a glance
| Generic name | Flu/Cy/ATG or Cy/ATG |
|---|---|
| Sponsor | Peking University People's Hospital |
| Drug class | Conditioning regimen (combination chemotherapy and immunosuppressive therapy) |
| Modality | Small molecule |
| Therapeutic area | Oncology / Hematology |
| Phase | FDA-approved |
Mechanism of action
Fludarabine is a purine analog that inhibits DNA synthesis in lymphocytes; cyclophosphamide is an alkylating agent that causes DNA cross-linking and cell death; and ATG is a polyclonal antibody that depletes T cells. Together, these agents create immunosuppression and myeloablation sufficient to allow engraftment of donor stem cells while reducing graft rejection and graft-versus-host disease.
Approved indications
- Conditioning prior to allogeneic hematopoietic stem cell transplantation for hematologic malignancies and severe aplastic anemia
Common side effects
- Myelosuppression / neutropenia
- Infection
- Mucositis
- Nausea and vomiting
- Graft-versus-host disease
- Hemorrhagic cystitis
Key clinical trials
- MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies (PHASE2)
- A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies (PHASE3)
- Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia (PHASE2, PHASE3)
- The Optimization of Conditioning Regimen for HLA Matched HSCT in SAA (PHASE4)
- The Optimization of Haploidentical Hematopoietic Stem Cell Transplantation
- Beijing Protocol in Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCT
- NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia (PHASE2)
- Intra-Osseous Co-Transplant of UCB and hMSC (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flu/Cy/ATG or Cy/ATG CI brief — competitive landscape report
- Flu/Cy/ATG or Cy/ATG updates RSS · CI watch RSS
- Peking University People's Hospital portfolio CI